Real‐World Long‐Term Outcomes of Rezūm Therapy for Large‐Volume Benign Prostatic Hyperplasia: A Multicenter Cohort Study
LUTS: Lower Urinary Tract Symptoms · 2026-07 · 18 (4)
DOI: 10.1111/luts.70079 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, online erschienen am 07.07.2026. Verfasst von Liberty Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Hyperthermia, Induced. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boston Scientific Corporation.
Abstract (Originalsprache)
Objectives
Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract symptoms (LUTS) in aging men. Patients with large prostates (≥ 80 mL) often experience more severe symptoms and have limited minimally invasive treatment options. Water vapor thermal therapy (Rezūm) has demonstrated efficacy in moderate‐sized glands, and emerging evidence including multicenter cohorts and systematic reviews suggests efficacy in larger glands. However, long‐term real‐world multicenter data remain limited. This study evaluates the effectiveness of Rezūm therapy in men urinary status outcomes, sexual function, and prostate size in a large, multicenter real‐world cohort with extended follow‐up.
Methods
We performed a retrospective analysis of a prospectively maintained multicenter registry including patients treated with Rezūm therapy between April 2019 and August 2025 at two high‐volume centers in Canada and Italy. Eligible patients had a baseline prostate volume ≥ 80 mL. Outcomes were assessed at baseline and follow‐up intervals of 6, 12, 24, and 36 months. Primary outcomes included changes in International Prostate Symptom Score (IPSS), quality of life (QoL), BPH Impact Index (BPHII), maximum urinary flow rate ( Q max ), and postvoid residual (PVR). Sexual function was evaluated using the International Index of Erectile Function (IIEF‐15) and the Male Sexual Health Questionnaire (MSHQ). Changes in prostate volume at 12 months were also analyzed.
Results
A total of 321 patients were included with a mean age of 68.7 years and median prostate volume of 107 mL. Median lobe enlargement was present in 80.1% of patients. Mean IPSS improved from 21.7 ± 6.9 at baseline to 9.9 ± 6.8 at 12 months and 8.4 ± 7.0 at 36 months ( p < 0.001), representing a symptom reduction of up to 62%. QoL scores improved from 4.5 ± 1.1 to 1.6 ± 1.2 at 36 months ( p < 0.001). Qmax increased from 8.1 ± 6.5 mL/s at baseline to 14.6 ± 6.7 mL/s at 6 months, while PVR decreased from 144 ± 136 mL to 48 ± 63 mL at 12 months. Erectile and ejaculatory function remained stable during follow‐up, with retrograde ejaculation reported in 6.2% of patients. Among 172 patients with imaging follow‐up, mean prostate volume decreased by 35.2 mL (29.9%) at 12 months.
Conclusions
Rezūm therapy provides significant and durable improvements in urinary symptoms and functional outcomes in men with large prostates (≥ 80 mL), while preserving sexual function. These findings support Rezūm as a safe and effective minimally invasive treatment option for large‐volume BPH in real‐world clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada.
- Division of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Canada.
- Plainview Hospital, Smith Institute of Urology, Northwell Health, Syosset, New York, USA.
- BPH Canada, Prostate Surgical Institute, Montreal, Canada.
- Urology Department, CUrE Group, Hesperia Hospital, Modena, Italy.
ORCID-Profile: Mario Henrique Bitar Siqueira, Naeem Bhojani, Luca Cindolo, Eviatar Fields, Dean Elterman
Förderung
- Boston Scientific Corporation
Zitieren
APA
Liu, L., Siqueira, M. H. B., Bhojani, N., Chughtai, B., Zorn, K. C., Cindolo, L., Ferrari, G., Lajkosz, K., Fields, E., & Elterman, D. (2026). Real‐World Long‐Term Outcomes of Rezūm Therapy for Large‐Volume Benign Prostatic Hyperplasia: A Multicenter Cohort Study. LUTS: Lower Urinary Tract Symptoms, 18(4). https://doi.org/10.1111/luts.70079
Vancouver
Liu L, Siqueira MHB, Bhojani N, Chughtai B, Zorn KC, Cindolo L, et al. Real‐World Long‐Term Outcomes of Rezūm Therapy for Large‐Volume Benign Prostatic Hyperplasia: A Multicenter Cohort Study. LUTS: Lower Urinary Tract Symptoms. 2026;18(4). doi:10.1111/luts.70079
BibTeX
@article{Liu2026,
author = {Liu, Liberty and Siqueira, Mario Henrique Bitar and Bhojani, Naeem and Chughtai, Bilal and Zorn, Kevin C and Cindolo, Luca and Ferrari, Giovanni and Lajkosz, Katherine and Fields, Eviatar and Elterman, Dean},
title = {Real‐World Long‐Term Outcomes of Rezūm Therapy for Large‐Volume Benign Prostatic Hyperplasia: A Multicenter Cohort Study},
journal = {LUTS: Lower Urinary Tract Symptoms},
year = {2026},
volume = {18},
number = {4},
doi = {10.1111/luts.70079}
}
EUVIMED